Japan's Ministry of Health, Labor and Welfare has increased by 3.7% to 22,951.5 billion yen ($211.15 billion) its fiscal year 2009 budget, compared to the initial figure asked for in 2008.
Although the increase includes a natural rise of 870.0 billion yen, such as for pension benefits, the MHLW will reduce this by 220.0 billion yen to 650.0 billion yen, mainly through the reform of the health care system and the promotion of the use of generic drugs.
With respect to allocations for pharmaceutical-related policies, 33.2 billion yen will be for promoting R&D of innovative drugs and medical devices, an increase of 5.8 billion yen compared to the pervious fiscal year. Within this, 29.0 billion yen will be allocated to drug and medical devices R&D in the areas of cancer, central nervous system diseases, orphan diseases, tailor-made therapies and regenerative medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze